Our research identifies AURKA as a key regulator of the immune response in GBM models, highlighting the potential for targeting this kinase in conjunction with immune-based therapies as a promising combination treatment strategy for this highly aggressive and difficult-to-treat brain cancer. Here, AURKA is linked to brain cancer.